Description:
Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals tracks deal-making and market opportunities in cell and gene therapy, providing specific details of 1000+ deals from 2022-2023. With a staggering $40 billion in CGT deals in 2022 alone, understanding the market dynamics and key players is essential for companies entering or already operating in this space.
Key Features:
- In-depth analysis of 1000+ Cell and Gene Therapy Deals from 2022-2023
- Overview of venture capital/private funding round amounts, by quarter
- Detailed breakdown of deal types, including Technology/Research/Strategic Collaboration, Venture Capital/Private Investment, Acquisition, Merger, Strategic Investment, and more
- Identification of the most active deal-making companies and their involvement in various types of deals
- Regional breakdown of deal-making activities in North America, Europe, APAC, and Rest of World
Market Insights:
The report provides insights into the trends shaping the cell and gene therapy market, including estimated market forecasts for cell and gene therapies by type (Gene Therapy, Cell Therapy), by region (North America, EU, APAC, Other), and by disease category. With over 1,500 companies involved in the industry, this report offers a comprehensive view of the competitive landscape and future growth opportunities.
Why Choose Kalorama’s Report:
Kalorama’s report offers unparalleled insights into the cell and gene therapy deal-making landscape, providing valuable information for companies seeking to capitalize on the market’s rapid growth. With detailed analysis of deal trends, funding amounts, and regional activities, this report is a must-have resource for companies looking to navigate the complex world of cell and gene therapy deal-making.
Conclusion:
As the cell and gene therapy market continues to evolve, understanding the deal-making landscape is crucial for identifying opportunities and staying competitive. Kalorama’s report provides a comprehensive overview of the current market dynamics, making it an essential resource for companies looking to succeed in this rapidly growing industry.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q1 2023($M) (%)
| Region | Q1 ’21 | Q2 | Q3 | Q4 | Q1 ’22 | Q2 | Q3 | Q4 | Q1 ’23 | Overall | Share |
| N. America | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Europe | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| APAC | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| ROW | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| # disclosing $ | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
| avg round | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information
